Injectable drug with chemoradiation to preserve the rectum in rectal cancer
Treatments studied
Part of Cancer, Digestive system clinical trials.
This trial tests an injectable drug (KORTUC) given directly into the tumor along with standard chemoradiation for locally advanced rectal cancer. The goal is to shrink the tumor so that surgery may not be needed, aiming to preserve the rectum.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 18 years old or older and have rectal cancer that has not spread elsewhere.
- Your rectal cancer is locally advanced (Stage III), meaning it is large or involves nearby lymph nodes, and is considered high-risk.
- You are able to receive a combination of chemotherapy (called CAPOX or FOLFOX) and radiation therapy.
- The tumor can be reached with a needle for the study injections and is visible on an endoscopic exam.
- You have not had prior radiation to the pelvis, prior rectal surgery, or other experimental treatments for rectal cancer.
- You agree to use effective birth control if you or your partner could become pregnant.
- You are in generally good health (able to carry on daily activities) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new approach for people with locally advanced rectal cancer that has high-risk features. It combines short-course radiation with chemotherapy (CapeOX) and the immunotherapy drug toripalimab, with or without another drug called surufatinib, before surgery. The goal is to see if adding these drugs helps shrink the tumor and improve outcomes.
This trial tests a new treatment sequence for locally advanced rectal cancer: a short course of radiation followed by a combination of immunotherapy (cadonilimab) and chemotherapy (mFOLFOX6) before surgery. The goal is to shrink the tumor more effectively and potentially improve outcomes.
This trial tests a combination of short-course radiation, chemotherapy (CapeOx), and an immunotherapy drug (PD-1 inhibitor) for people with early-stage rectal cancer who have had a local excision but are at high risk of the cancer coming back. The goal is to avoid more extensive surgery while still effectively treating the cancer.
This trial tests whether a newer approach can treat early-stage rectal cancer without removing the whole rectum, aiming to preserve bowel function. It compares different treatment options to see which is safest and most effective.
This study compares two treatment approaches for patients with locally advanced rectal cancer. One group gets a short course of radiation followed by chemotherapy combined with an immunotherapy drug called a PD-1 inhibitor, while the other group gets radiation and chemotherapy alone. The trial aims to see if the PD-1 inhibitor improves outcomes and whether a natural substance in the blood called beta-hydroxybutyrate can predict response.
This trial tests combining standard chemotherapy and radiation with an immunotherapy drug (QL1706) before surgery for low rectal cancer. The goal is to see if this approach shrinks tumors more effectively and improves outcomes.
Hear when a new Rectal Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.